Haleon tops FTSE 100 fallers after downgrade

Haleon PLC shares fell 3% after Barclays downgraded the consumer health group to "equal weight" from "overweight," cutting its price target to 380p from 430p. The downgrade is primarily driven by concerns over Haleon's significant exposure to a challenging US market, which accounts for a third of its sales and is experiencing slower growth and retailer destocking. Barclays is skeptical of Haleon's revised 2025 organic sales growth target of 3.5%, forecasting only 3.1%, and highlights additional headwinds in Latin America and Europe, asserting that margin improvements alone will not drive outperformance without a recovery in the crucial US market.

Analysis

Haleon PLC's shares declined 3% to 345.9p, becoming the top FTSE 100 faller, following a significant downgrade by Barclays from “overweight” to “equal weight” with a price target reduction to 380p from 430p. The core of Barclays' negative thesis is centered on Haleon's largest market, the United States, which constitutes approximately one-third of group sales. This region is experiencing slowing category growth and retailer destocking, pressures that Barclays warns could intensify in the second half of the year. This skepticism directly challenges Haleon's ability to meet its own revised 2025 organic sales growth target of 3.5% (down from 4%), with Barclays forecasting a more pessimistic 3.1%. The headwinds are not isolated; the bank also highlights emerging risks from consumer trade-downs in Latin America and pricing pressure in Germany. While the strong performance of oral care brands like Sensodyne and an £800 million cost-saving plan are bolstering margins, Barclays concludes that profit growth alone is insufficient to drive stock outperformance without a clear recovery in the US market, noting a preference for competitor Unilever PLC for its more convincing strategic plan.

Key Decisions for Investors

• Investors should closely monitor near-term US retail channel data and inventory levels, as the analysis indicates a turnaround in this key market is the primary catalyst required for the stock to outperform.
• The discrepancy between Haleon's 3.5% organic growth guidance and Barclays' 3.1% forecast highlights a significant execution risk; failure to demonstrate growth acceleration in the second half could trigger further negative revisions.
• Given the explicit preference for Unilever by the analyst, investors might consider a relative value analysis between Haleon and Unilever, as the latter is perceived to have a more credible strategy for achieving similar growth targets.
• While top-line growth faces headwinds, the ongoing £800 million cost-saving plan provides a degree of support for margins and earnings, a factor that may appeal to long-term investors willing to tolerate near-term volatility.